News
The following year, the US regulatory agency expanded the Kisqali label to HR+/HER2- advanced or metastatic breast cancer irrespective of the patient’s menopausal status. The FDA also approved ...
Hosted on MSN6mon
Novartis Gets CHMP Recommendation for Kisqali in Broader PopulationA potential approval of Kisqali will provide an effective and ... $1.3 billion in the first half of 2024. Last year, the FDA also expanded Eli Lilly’s LLY Verzenio’s (abemaciclib) indication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback